Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out
A little over 3 years ago, Merck splashed into a licensing deal with AstraZeneca covering their blockbuster Lynparza franchise with $1.6 billion in cash upfront. Until today, that was by far the biggest single collaboration that Merck has seen in the past 12 years.
I asked Chris Dokomajilar at DealForma to update the charts on Merck, and as you can see below, the deal that the pharma giant just conceived with Seattle Genetics on a LIV1 ADC — with another $1.6 billion for an upfront and equity — dwarfs anything else out there that registered on the experimental side since 2008.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.